ClinicalTrials.gg
CompletedNCT03038178Updated Mar 4, 2020

Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease

A Phase 2 interventional study of LAI plus multi-drug regimen in Mycobacterium Infections, Nontuberculous and Mycobacteria, Atypical, sponsored by Kevin Winthrop. Completed at 2 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2020-03-04.

Sponsored by Kevin Winthrop · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Oct 2016, registered Jan 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Mycobacterium Infections, Nontuberculous with a site in United States — 7 open to participants now, 7 under way, none of them phase 3. Mycobacterium Infections, Nontuberculous · United States.

Planned enrollment
14th of 18
30 · median 58
Started
2016
the only one that year
Phase 2
10 of 24
3 open now
Registered
9th of 24
by date
Lead sponsor
3 of 24
Kevin Winthrop

Among the 24 studies in Mycobacterium Infections, Nontuberculous with a site in United States, this one is the 14th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2016, is one of 10 in phase 2, and was the 9th registered.

Mycobacterium Infections, Nontuberculous

54 studies on the registry are indexed under Mycobacterium Infections, Nontuberculous; 19 are open to participants now.

Browse Mycobacterium Infections, Nontuberculous studies →

Open to participants now

7 of the 24 studies in Mycobacterium Infections, Nontuberculous with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Mycobacterium Infections, Nontuberculous studies recruiting now, 8 (67%) set no upper age limit and 2 (17%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Mycobacterium Infections, Nontuberculous with a site in United States, or all of them as a file.
02

Study summary

The proposed study will assess the efficacy, safety and tolerability of once daily dosing of Liposomal-Amikacin for Inhalation (LAI) 590 mg for 12 months plus standard of care (SOC) mycobacterial multi-drug regimen in accordance with the 2007 ATS/ IDSA guidelines, for treatment of mycobacterium abscessus lung disease.

Read the detailed description

This is an open-label study of efficacy, safety and tolerability of once daily dosing of Liposomal-Amikacin for Inhalation (LAI), in addition to a standard multi-drug antibiotic therapy in accordance with the 2007 ATS/ IDSA guidelines, in patients with Mycobacterium abscessus lung disease. The multi-drug therapy is determined at the discretion of the Investigator. After screening, all eligible patients will enter the trial and will receive LAI 590 mg once daily for 12 months. If deemed necessary by the investigator, dose may be adjusted from a minimum of three times per week up to daily, in cases of adverse events relating to tolerability.

All patients who enter the study will have subsequent study visits at Months 1,2,4,6,9, at End-of-Study or Month 12, and at 1 and 3 months post study drug discontinuation. At each visit (including screening), review of concomitant medications, review of adverse events, and physical exam, will be performed. Chest CT scan will be performed at baseline, 6 months, and 12 months, unless a chest CT scan has already been performed within 6 months on this time point. The 6 minute walk test and QOL-B-NTM will be performed at baseline, 6 months, 12 months, and 3 months post study drug discontinuation. All patients will have inducted sputum collected at each study visit, and patients will self-collect expectorated sputum during intervening monthly time-points until study completion to determine changes in mycobacterial smear and culture status.

Unscheduled visits will occur as needed should subjects' symptoms worsen between visits.

03

Conditions studied

  • Mycobacterium Infections, Nontuberculous
  • Mycobacteria, Atypical

Keywords

  • Mycobacterium Infections, Nontuberculous
  • Mycobacteria, Atypical
  • Amikacin
  • Inhalation
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients 12 years and older
  • Diagnosis of M. abscessus, including all subspecies, abscessus, bolleti, and massiliense lung disease according to the 2007 ATS/IDSA criteria
  • Both newly diagnosed and currently on treatment or previously treated patients will be included
  • Culture positive (either sputum or bronchoscopy) for M. abscessus at time of screening
  • Willingness to adhere to a treatment regimen, study visits, and study procedures during the course of the study.
  • Ability to produce at approximately 3.0 mL of sputum or be willing to undergo an induction that produces approximately 3.0 mL of sputum for culture collection
  • Female of agrees to practice an acceptable method of (e.g., abstinence, hormonal or barrier methods, partner sterilization, or IUD)
  • Written or assent obtained from the patient, parent or legal guardian prior to the performance of any study related procedures

Exclusion criteria

Exclusion Criteria:

  • Active pulmonary tuberculosis requiring treatment at screening
  • Treatment with inhaled or intravenous Amikacin within 14 days prior to baseline
  • Known to aminoglycosides
  • or alanine aminotransferase ≥ 3 times the or total ≥ 2 times the upper limit of normal (ULN) at screening
  • Current addiction to alcohol or illicit drug abuse
  • Any condition which in the opinion of the Investigator interferes with ability to adhere to study requirements
  • Primary immunodeficiency syndromes and acquired immunodeficiency syndromes (e.g., -positive patients regardless of )
  • ≤500/μL at Screening
  • Significant (as determined by the investigator) hearing loss, vestibular dysfunction, neuromuscular weakness or a diagnosis of myasthenia gravis, where the potential risk of aminoglycoside toxicity outweighs the potential benefit
  • Serum creatinine >2 times ULN at Screening
  • History of lung transplantation
  • Any condition that, in the judgment of the Investigator, would compromise the ability of the subject to complete the study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    LAI plus multi-drug regimen

    once daily dosing of Liposomal-Amikacin for Inhalation (LAI) 590 mg for 12 months plus standard of care (SOC) mycobacterial multi-drug regimen in accordance with the 2007 ATS/ IDSA guidelines

    Drug: LAI plus multi-drug regimen

Interventions

  • DrugLAI plus multi-drug regimen

    Drug page: AmikacinStudies of AmikacinAmikacin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Liposomal Amikacin for Inhalation (LAI) is the experimental treatment which, in this single arm will be taken in conjunction with standard of care multi-drug treatment regimen

    Also known as: ARIKAYCE™

06

What researchers measure

Primary outcomes

  1. Change from Baseline sputum culture at 12 months

    Time frame: Sputum examined for culture change from Baseline at 12 months

Secondary outcomes

  1. Change from Baseline 6-minute Walk Test at 6 months

    Time frame: 6-minute Walk Test results examined for change from Baseline at 6 months

  2. Change from Baseline 6-minute Walk Test at 12 months

    Time frame: 6-minute Walk Test results examined for change from Baseline at 12 months

  3. Change from End of Treatment (EOT) sputum culture at 3 months post EOT

    Time frame: Sputum examined for culture change from EOT at 3 months post EOT

  4. Number of Hospitalizations for pulmonary exacerbations

    Time frame: Number of Hospitalizations for pulmonary exacerbations that occur between Baseline and 12 months

  5. Number of Adverse Events

    Time frame: Number of Patient-reported and Investigator-reported Adverse Events at 12 months

  6. Number of subjects discontinuing study drug due to Adverse Event

    Time frame: Number of subjects who discontinue study drug before 12 months due to Adverse Event will be examined at 12 months

Other outcomes

  1. Change from Baseline reported nontuberculous mycobacterium (NTM) symptoms at End of Treatment (EOT)

    Time frame: Patient-reported NTM symptoms examined for change from Baseline at EOT (12 months)

  2. Change from Baseline Chest CT at End of Treatment (EOT)

    Time frame: CT scan examined for change from Baseline at EOT (12 months)

  3. Change from Baseline body weight at End of Treatment (EOT)

    Time frame: body weight of patient examined for change from Baseline at EOT (12 months)

  4. Change from Baseline Body Mass Index (BMI) at End of Treatment (EOT)

    Time frame: BMI of patient examined for change from Baseline at EOT (12 months)

07

Study locations

2 sites
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • University of Texas Health Science Center
    Tyler, Texas 75708, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2016 to primary completion in Oct 2019, 36 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2017
First posted
Jan 31, 2017
StartActual
Oct 2016
Primary completionActual
Oct 31, 2019
CompletionActual
Dec 31, 2019
Last update
Mar 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03038178
Lead sponsor
Kevin Winthrop
Collaborators
Insmed Incorporated, The University of Texas Health Science Center at Tyler
Responsible party
Kevin Winthrop (Associate Professor, Oregon Health and Science University) — Sponsor-investigator
First posted
Jan 31, 2017
Start date
Oct 2016
Primary completion
Oct 31, 2019
Completion
Dec 31, 2019
Last update
Mar 4, 2020

Study contacts

Kevin L Winthrop, MD, MPH
principal investigator · Oregon Health and Science University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amikacin

Start the discussion